Change in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: change in scores from baseline to endpoint (12 weeks) on symptom rating scales in the treatment of manic and mixed episodes Lower scores indicate improvement · adults with acute affective episodes in bipolar disorder
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
Topiramate plus ASMs showed no clear difference in number of participants with ≥ 75% reduction in all seizures compared with placebo plus ASMs (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in body weight as compared to placebo (%) from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania
Lithium leads to higher efficacy: response (categorical) YMRS change ≥ 50% from baseline to… compared with topiramate (high certainty).
1 finding from 1 review
Efficacy: response (continuous) YMRS change by ≥ 50% at end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Remission · acute mania
Lithium leads to higher efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with topiramate (high certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with topiramate (high certainty).
1 finding from 1 review
Intervention not reported
Functional disability ( · people with essential tremor
1 finding from 1 review
Intervention not reported
Study withdrawal ( · people with essential tremor
The intervention may leads to higher study withdrawal ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ( · people with essential tremor
1 finding from 1 review